Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor
PR Newswire Asia
SHANGHAI, May 24, 2024 /PRNewswire/ -- Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and..